A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 3, 2003, Pages 1280-1284

  Gadi, Vijayakrishna K ^a,b   Alexander, Sherrie D ^b   Waud, William R ^c   Allan, Paula W ^c   Parker, William B ^c   Sorscher, Eric J ^a,b,d  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYLPURINE; 9 BETA DEXTRO (2 DEOXYRIBOFURANOSYL) 6 METHYLPURINE; DRUG METABOLITE; PRODRUG; PURINE NUCLEOSIDE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; DRUG ACTIVATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; ESCHERICHIA COLI; GENETIC TRANSDUCTION; GLIOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUICIDE GENE; SUICIDE GENE THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; GLIOMA; HUMANS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PURINES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037370192     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.044743     Document Type: Article

References (30)

1. Andreansky SS, He B, Gillespie GY, Soroceanu L, Market J, Chou J, Roizman B, and Whitley RJ (1996) The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 93:113113-113118.
2. Beck C, Cayeux S, Lupton SD, Dorken B, and Blankenstein T (1995) The thymidine kinase/ganciclovir-mediated "suicide" effect is variable in different tumor cells. Hum Gene Ther 6:1525-1530.
3. Bradbury NA, Jilling T, Berta G, Sorscher EJ, Bridges RJ, and Kirk KL (1992) Regulation of plasma membrane recycling by CFTR. Science (Wash DC) 256:530-532.
4. DeVita VT, Hellman S, and Rosenberg SA (1997) Cancer: Principles & Practice of Oncology, 5th ed, vol 2, Lippincott-Raven, Philadelphia.
5. Dilber MS, Abedi MR, Christensson B, Bjorkstrand B, Kidder GM, Naus CC, Gahrton F, and Smith CI (1997) Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res 57:1523-1528.
6. Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, et al. (1998) Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 4:1887-1898.
7. Dykes DJ, Abbott BJ, Mayo JG, Harrison SD Jr, Laster WR Jr, Simpson-Herren L, and Griswold DP Jr (1992) Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib Oncol 42:1-22.
8. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, Amin KM, Kaiser LR, and Albelda SM (1996) Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 3:85-92.
9. Fick J, Barker FN, Dazin P, Westphale EM, Beyer EC, and Israel MA (1995) The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Nat Acad Sci USA 92:11071-11075.
10. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, and Abraham GN (1993) The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53:5274-5283.
11. Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, and Sorscher EJ (2000) In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther 7:1738-1743.
12. Giangaspero F, Doglioni C, Rivano MT, Pileri S, Gerdes J, and Stein H (1987) Growth fraction in human brain tumors defined by the monoclonal antibody Ki-67. Acta Neuropath 74:179-182.
13. Huber BE, Austin EA, Richards CA, Davis ST, and Good SS (1994) Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Nat Acad Sci USA 91:8302-8306.
14. Hughes B, Parker WB, Gadi VK, Garver RI, and Sorscher EJ (1995) Tumor specific killing with high bystander toxicity using the human tyrosinase promoter to express the E. coli PNP gene. Cancer Res 55:3339-3345.
15. Hughes BW, King SA, Allan PW, Parker WB, and Sorscher EJ (1998) Cell to cell contact is not required for bystander cell killing by E. coli purine nucleoside phosphorylase. J Bio Chem 273:2322-2328.
16. Imaizumi K, Hasegawa Y, Kawabe T, Emi N, Saito H, Naruse K, and Shimokata K (1998) Bystander tumoricidal effect and gap junctional communication in lung cancer cell lines. Am J Respir Cell Mol Biol 18:205-212.
17. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, Russell P, Both GW, Molloy PL, Lockett LJ, and Russell PJ (1998) In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gen Ther 9:1617-1626.
18. Miller AD and Rosman GJ (1989) Improved retroviral vectors for gene transfer and expression. Biotechniques 7:980-990.
19. Montgomery AD and Rosman GJ (1968) Analogs of 6-methyl-9-β-D-ribofuranosylpurine. J Med Chem 11:48-52.
20. Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, and Bennett LL (1998) Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 55:1673-1681.
21. Parker WB, King SA, Allan PW, Bennett LL Jr, Secrist JA III, Montgomery JA, Gilbert KS, Waud WR, Wells AH, Gillespie GY, and Sorscher EJ (1997) In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum Gene Ther 8:1637-1644.
22. Puhlmann M, Gnant M, Brown CK, Alexander HR, and Bartlett DL (1999) Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther 10:649-657.
23. Ram Z, Culver KW, Walbridge S, Blaese RM, and Oldfield EH (1993) In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53:83-88.
24. Sacco MG, Benedetti S, Duflotdancer A, Mesnil M, Bagnasco L, Strina D, Fasolo V, Villa A, Macchi P, Faranda S, et al. (1996) Partial regression, yet incomplete eradication of mammary tumors in transgenic mice by retrovirally mediated HSV-tk transfer in vivo. Gene Ther 3:1151-1156.
25. Sadi MV and Barrack ER (1991) Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer 67:3065-3071.
26. Secrist JA, Parker WB, Allan PW, Bennett LL, Waud WR, Truss JW, Fowler AT, Montgomery JA, Ealick SE, Wells AH, et al. (1999) Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase. Nucleosides Nucleotides 18:745-757.
27. SEER Cancer Incidence Public Use Database 1973-1996 (1999) United States Public Health Service, Washington, DC.
28. Springer CJ and Niculescu-Duvaz I (2000) Prodrug-activating systems in suicide gene therapy. J Clin Inuestig 105:1161-1167.
29. Tapscott SJ, Miller AD, Olson JM, Berger MS, Groudine M, and Spence AM (1994) Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Nat Acad Sci 91:8185-8189.
30. Vescio RA, Connors KM, Bordin GM, Robb JA, Youngkin T, Umbreit JN, and Roffman RM (1990) The distinction of small cell and non-small cell lung cancer by growth in native-state histoculture. Cancer Res 50:6095-6099.